TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03808909

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Labor Support
Description: Participants in the intervention condition will be assigned a doula who is a lay person trained to provide emotional and practical support to individuals throughout labor and delivery.
Study: NCT02298504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate
Description: Vital pulp therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biodentin
Description: Vital pulp therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitrebond
Description: Vital pulp therapy
Study: NCT02979158

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPB Low Dose
Description: Performing CPB with low dose heparin and coated equipment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPB High Dose
Description: Performing CPB with high dose heparin and uncoated equipment
Study: NCT01898091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neem Mouthrinse
Description: 10ml dose of assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Mouthrinse
Description: 10ml dose of assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Mouthrinse
Description: 10ml dose of assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
Study: NCT03864549

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Femina II
Description: 2 capsules per day until delivery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules per day until delivery
Study: NCT01618708

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synvisc-One (hylan G-F 20)
Description: 6-mL IA injection

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 mL injection of phosphate buffered saline
Study: NCT03471949

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CGM in a population with normal OGTT
Description: The population with normal OGTT will use CGM and document their values as well as be documenting a capillary blood glucose value
Study: NCT02218268

Intervention type: DRUG
Intervention: Pre-meal bolus
Description: Long acting insulin as scheduled per usual routine PLUS rapid/ short acting (bolus) prior to Boost

Intervention type: DRUG
Intervention: Pre-meal bolus
Description: Long acting insulin as scheduled per usual routine PLUS rapid/ short acting (bolus) prior to Boost

Intervention type: DRUG
Intervention: No meal bolus
Description: Long Acting insulin as scheduled per usual routine (given once daily)

Intervention type: DRUG
Intervention: No meal bolus
Description: Long Acting insulin as scheduled per usual routine (given once daily)
Study: NCT00356421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Human Insulin (Exubera®)
Description: Preprandial inhaled insulin regimen and administration of insulin glargine QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin lispro (Humalog)
Description: Subcutaneous insulin regimen of pre-prandial insulin lispro and administration of insulin glargine QD.
Study: NCT03941886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin in women with high risk of preeclampsia
Description: Low-dose aspirin 150-162 mg/night or 100 mg/night if body weight \<40 Kg, from \<15 weeks till 36 weeks or, in the event of early delivery, at the onset of labor
Study: NCT04291833

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention group 1
Description: Protein supplementation BID, Vitamin D and calcium supplementation Vitamin D 2000 IU / d, calcium 1000mg/d, exercise 6 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention group 2
Description: Protein supplementation QD, Vitamin D and calcium supplementation Vitamin D 1000 IU / d, calcium 500mg/d, exercise 3 months

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group 0
Description: no protein supplementation , no Vitamin D and calcium supplementation , no exercise
Study: NCT02694250

Intervention type: DEVICE
Group type: OTHER
Intervention: DTRAX® Cervical Cage with DTRAX Bone Screw
Description: DTRAX Cervical Cage is an intervertebral fusion device that provides mechanical support to the spine. DTRAX Cervical Cage is intended to be used in cervical spine fusion surgery. DTRAX Bone Screw is indicated for use in arthrodesis and provides supplemental fixation. .
Study: NCT03854032

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IDO1 Inhibitor BMS-986205
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo Surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Undergo Surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00430859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alkaline Phosphatase
Description: Intravenous over a period of 24 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline over a period of 24h
Study: NCT00887588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: 50 mg, 100 mg and 200 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: 40 mg, 80 mg and 160 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo to LCZ696 and Valsartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: matching placebo to LCZ696 and Valsartan
Study: NCT03335566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonazoid™
Description: Single Dose of Sonazoid™ 0.12 µL MB/kg as I.V. injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SonoVue®
Description: Single Dose of SonoVue® 2.4 mL as I.V. injection.
Study: NCT00663351

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reflection Ceramic-Ceramic Total Hip Replacement
Description: Intervention: all patients in study required (intervention) a total hip replacement, and were randomized to receive either the (Study Device)Reflection Ceramic Acetabular System or the(Control Device) Reflection FSO V (5 hole)acetabular system. Both arms received either a Synergy porous coated or Spectron EF stem.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reflection FSO V Total Hip Replacement
Description: Intervention: all patients in study required (intervention) a total hip replacement, and were randomized to receive either the (Study Device)Reflection Ceramic Acetabular System or the(Control Device) Reflection FSO V (5 hole)acetabular system. Both arms received either a Synergy porous coated or Spectron EF stem.
Study: NCT02072993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1979
Description: Single dose, oral solution administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match
Description: Single dose, oral solution administration
Study: NCT03536065

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opioid Reduction Intervention
Description: Patient education discharge sheet, nursing education, opioid prescription reduction based on Pre-Intervention data

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Current Care
Description: Current unchanged care provided; unchanged provider prescribing and unchanged education of patients prior to intervention
Study: NCT03000751

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simple Audit Report
Description: The simple audit provides comparison and feedback on radiation doses.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simple Audit Report
Description: The simple audit provides comparison and feedback on radiation doses.

Intervention type: OTHER
Group type: OTHER
Intervention: Simple Audit Report
Description: The simple audit provides comparison and feedback on radiation doses.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multi-Component Intervention
Description: The multi-component intervention gives tailored feedback on needed changes plus guidance using quality improvement methods that facilitate organizational change. Provides access to experts, detailed audit, collaborative calls, and site visits (as needed).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multi-Component Intervention
Description: The multi-component intervention gives tailored feedback on needed changes plus guidance using quality improvement methods that facilitate organizational change. Provides access to experts, detailed audit, collaborative calls, and site visits (as needed).

Intervention type: OTHER
Group type: OTHER
Intervention: Multi-Component Intervention
Description: The multi-component intervention gives tailored feedback on needed changes plus guidance using quality improvement methods that facilitate organizational change. Provides access to experts, detailed audit, collaborative calls, and site visits (as needed).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-Person Meeting
Description: Collaborator meeting with an emphasis on quality improvement.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-Person Meeting
Description: Collaborator meeting with an emphasis on quality improvement.
Study: NCT00962455

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-learning & performance feedback
Description: Initial e-learning by studying CD-Rom 'Spirometry Fundamentals', followed by repeated periodic performance feedback on spirometry test quality

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual practice
Description: Usual practice regarding spirometry execution in family practice
Study: NCT02245386

Intervention type: RADIATION
Intervention: transperineal pelvic floor ultrasound
Description: Transperineal pelvic floor ultrasound applied for the submitted 120 women primiparae (40 women after normal vaginal delivery), (40 women after urgent cesarean section), (40 women after elective cesarean section), in early postpartum period (48 to 72) hours postpartum, to evaluate levator ani morphology.

Intervention type: RADIATION
Intervention: transperineal pelvic floor ultrasound
Description: Transperineal pelvic floor ultrasound applied for the submitted 120 women primiparae (40 women after normal vaginal delivery), (40 women after urgent cesarean section), (40 women after elective cesarean section), in early postpartum period (48 to 72) hours postpartum, to evaluate levator ani morphology.

Intervention type: RADIATION
Intervention: transperineal pelvic floor ultrasound
Description: Transperineal pelvic floor ultrasound applied for the submitted 120 women primiparae (40 women after normal vaginal delivery), (40 women after urgent cesarean section), (40 women after elective cesarean section), in early postpartum period (48 to 72) hours postpartum, to evaluate levator ani morphology.
Study: NCT02499536

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: Juxtapleural consolidation, loss of A lines, presence of B lines, air bronchogram, loss of sliding sign and presence of pulse sign on lung ultrasound finding will be investigated and recorded.
Study: NCT02552654

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Film
Description: Film scene with severe physical and sexual violence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Film
Description: Film scene with severe physical and sexual violence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01016015

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study: NCT03993678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IP-001
Description: Dose and route: Immediately (within 15 - 30 min) after thermal ablation, IP-001 will be injected in and around the ablated lesion. The amount of IP-001 injected depends on the dose level.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal Ablation
Description: The medical device includes a laser unit. The system continuously measures the temperature of the tissue, guiding the user to perform precise and safe treatments.~Treatment time: 30 min
Study: NCT02051283

Intervention type: OTHER
Intervention: RFA
Description: RFA
Study: NCT01972984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Participants will be instructed to take one tablet of anastrozole orally per day with fluids. This tablet will be taken at the same time every day. Participants will be given a drug diary to record drug administration and aid in drug compliance. Should the participant miss a dose they will be asked to record it in their diary and resume the normal dose schedule the next day.
Study: NCT02470377

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: A form of external neuromodulation using pulsatile magnetic fields on the surface of the head.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: A form of external neuromodulation using pulsatile magnetic fields on the surface of the head.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: A form of external neuromodulation using pulsatile magnetic fields on the surface of the head.
Study: NCT03274661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg Q3W
Description: Pembrolizumab 200 mg Intravenous Infusion every 3 weeks administered on Day 1 of each 3 week cycle
Study: NCT00211900

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S. aureus Type 5 & 8 Capsular Polysaccharide Vaccine
Description: single IM dose totalling 200 mcg of conjugate
Study: NCT03750669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG regimen
Description: Combination of Nab-paclitaxel 125 mg/m\^2 and Gemcitabine 1000 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFolfirinox
Description: Folic acid 400mg/m\^2, 5- fluorouracil 2400mg/m\^2 for 46h, irinotecan 135mg/m\^2 and oxaliplatin 68mg/m\^2
Study: NCT02425488

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing therapeutics education
Description: Educational intervention will focus on~1. Appropriate lifestyles~2. Early recognition of signs/prodromal symptoms of HF~3. Early recognition of signs of inflammation of the ICD-pocket~4. Good management of the device~1) Therapy, body weight, diet, smoking, alcohol, rest, exercise, job and sex 2) Dyspnea, edema and fovea, rapid weight gain, loss of appetite, fatigue, asthenia, insomnia, mental confusion 3) Signs and symptoms of inflammation: hyperpyrexia, rubor, dolor, calor and tumor 4) Identification tag, vibration, metal detectors, air travel, use of electronic devices, diagnostic PET and MRI
Study: NCT04679818

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Routine opioid management
Description: Clinical judgement will be according to their standard practice and may include interpretation of blood pressure, heart rate, diaphoresis, tearing, and pupil size. Boluses of fentanyl 1 µg/kg actual body weight (ABW), up to a maximum dose of 100 µg per bolus, can be given per clinical judgement.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PMD-200 Nol-guided opioid administration
Description: PMD-200 Nociception level (NOL) values exceeding 25 for more than 30 seconds will typically be treated with boluses of fentanyl 1µg/kg ABW, up to a maximum of 100 µg per boluses, 5-minute intervals. Towards the end of the surgery (approximately 30-45 minutes before end of surgery, based on clinical judgment), the boluses of fentanyl will be reduced to 0.5 µg/kg ABW, up to a maximum of 50 µg per boluses, 5 minutes intervals. The target of a PMD-200 NOL score below 25 will be maintained until surgery ends
Study: NCT01829607

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional electrical stimulation of peripheral muscles
Study: NCT03475563

Intervention type: PROCEDURE
Intervention: Coronary angioplasty with stent implantation
Description: Coronary angioplasty with BiOSS LIM C stent implantation
Study: NCT00689286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BION
Description: They will be divided into three groups. Two groups of experimental subjects will receive stimulation using BIONs. The first group will have a stimulation paradigm like that used in a previous feasibility study that preceded the proposed trial, using low-frequency (1-5 PPS) twitch stimulation. The second group will have a stimulation paradigm in which tetanic-frequency stimulation (25-50 PPS) is used to produce fused muscle contractions. A third group of experimental subjects will have a standardized program of voluntary exercise.~In Groups 1 and 2, the femoral nerve will be stimulated electrically according to the assigned protocol during the 12 week experimental period after implantation of the devices. Individuals assigned to Group 3, receiving conventional exercise therapy for 12 weeks, will be allowed to receive BIONs at the end of the trial, providing they request BION therapy and they have been at least minimally compliant with the exercises.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BION
Description: They will be divided into three groups. Two groups of experimental subjects will receive stimulation using BIONs. The first group will have a stimulation paradigm like that used in a previous feasibility study that preceded the proposed trial, using low-frequency (1-5 PPS) twitch stimulation. The second group will have a stimulation paradigm in which tetanic-frequency stimulation (25-50 PPS) is used to produce fused muscle contractions. A third group of experimental subjects will have a standardized program of voluntary exercise.~In Groups 1 and 2, the femoral nerve will be stimulated electrically according to the assigned protocol during the 12 week experimental period after implantation of the devices. Individuals assigned to Group 3, receiving conventional exercise therapy for 12 weeks, will be allowed to receive BIONs at the end of the trial, providing they request BION therapy and they have been at least minimally compliant with the exercises.
Study: NCT01801605

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: rTMS
Description: Active session with stimulation and placebo session with fictive stimulation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: Active session with stimulation and placebo session with fictive stimulation
Study: NCT02914223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenerimod
Description: Oral formulation of cenerimod (2mg) containing 100 μCi (3.7 MBq) of 14C-radiolabeled cenerimod

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenerimod
Description: Oral formulation of cenerimod (2mg) containing 100 μCi (3.7 MBq) of 14C-radiolabeled cenerimod
Study: NCT02922660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desflurane
Description: method of anesthesia maintenance with desflurane ranged from 0.5\~1.5 MAC during the procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total intravenous anesthesia
Description: method of anesthesia in group TIVA is total intravenous anesthesia(TIVA) during the procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: inhalation anesthesia
Description: method of anesthesia in group DES is inhalation anesthesia with desflurane during the procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: using propofol as sedative during the procedure of anesthesia and maintaining with propofol Cp 2-4 μg/ml in TCI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: using remifentanil as analgesics during the procedure of anesthesia and maintaining with remifentanil 2-4 ng/ml in TCI
Study: NCT03450135

Intervention type: BEHAVIORAL
Intervention: Trier Social Stress Test
Description: Participants will perform an acute psychosocial stress manipulation (Trier Social Stress Test) involving a speech task and challenging mental arithmetic.

Intervention type: BEHAVIORAL
Intervention: Emotional go/no-go task
Description: Participants will perform an emotional go/no-go paradigm to examine electrophysiological (EEG) correlates of cognitive and affective processing.
Study: NCT01968408

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri DSM 17938
Description: 10(9) CFU/daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02477046

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tOPV
Description: administered per protocol

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bOPV
Description: administered per protocol

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bOPV
Description: administered per protocol

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPV
Description: administered per protocol

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPV
Description: administered per protocol

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPV
Description: administered per protocol
Study: NCT03189433

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ryanodex (dantrolene sodium) for injectable suspension
Description: Ryanodex (dantrolene sodium) for injectable suspension, 250 mg/vial to be reconstituted in 5 mL of sterile water for injection to yield a 50 mg/mL suspension that will be administered as a rapid IV push of 2.5 mg/mL.